A detailed history of Rhumbline Advisers transactions in Pulmonx Corp stock. As of the latest transaction made, Rhumbline Advisers holds 52,642 shares of LUNG stock, worth $333,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,642
Previous 50,908 3.41%
Holding current value
$333,750
Previous $649,000 24.96%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$8.71 - $14.65 $15,103 - $25,403
1,734 Added 3.41%
52,642 $487,000
Q4 2023

Feb 08, 2024

BUY
$7.89 - $13.14 $15,598 - $25,977
1,977 Added 4.04%
50,908 $649,000
Q3 2023

Nov 09, 2023

SELL
$9.88 - $14.0 $12,103 - $17,150
-1,225 Reduced 2.44%
48,931 $505,000
Q2 2023

Aug 08, 2023

BUY
$10.78 - $13.65 $52,455 - $66,420
4,866 Added 10.74%
50,156 $657,000
Q1 2023

May 11, 2023

BUY
$7.49 - $12.54 $11,856 - $19,850
1,583 Added 3.62%
45,290 $506,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $17.35 $6,710 - $23,665
1,364 Added 3.22%
43,707 $368,000
Q3 2022

Nov 10, 2022

BUY
$15.35 - $23.99 $47,477 - $74,201
3,093 Added 7.88%
42,343 $705,000
Q2 2022

Aug 11, 2022

BUY
$14.0 - $27.95 $175,686 - $350,744
12,549 Added 47.0%
39,250 $578,000
Q1 2022

May 12, 2022

BUY
$21.13 - $35.65 $34,167 - $57,646
1,617 Added 6.45%
26,701 $662,000
Q4 2021

Feb 10, 2022

SELL
$29.72 - $45.1 $15,038 - $22,820
-506 Reduced 1.98%
25,084 $804,000
Q3 2021

Nov 12, 2021

BUY
$35.98 - $44.48 $44,867 - $55,466
1,247 Added 5.12%
25,590 $921,000
Q2 2021

Aug 05, 2021

BUY
$37.61 - $48.0 $443,346 - $565,824
11,788 Added 93.89%
24,343 $1.07 Million
Q1 2021

May 06, 2021

BUY
$44.0 - $67.54 $40,392 - $62,001
918 Added 7.89%
12,555 $574,000
Q4 2020

Feb 10, 2021

BUY
$39.31 - $69.02 $457,450 - $803,185
11,637 New
11,637 $803,000

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.